A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 9, Issue 6, 2010, Pages 1809-1819

  Dransfield, Daniel T ^a   Cohen, Edward H ^a   Chang, Qing ^a   Sparrow, Lindsay G ^b   Bentley, John D ^b   Dolezal, Olan ^b   Xiao, Xiaowen ^b   Peat, Thomas S ^b   Newman, Janet ^b   Pilling, Patricia A ^b   Phan, Tram ^b   Priebe, Ilka ^b   Brierley, Gemma V ^b   Kastrapeli, Niksa ^a   Kopacz, Kris ^a   Martik, Diana ^a   Wassaf, Dina ^a   Rank, Douglas ^a   Conley, Greg ^a   Huang, Yan ^a   Adams, Timothy E ^b   Cosgrove, Leah ^b   more..

^a Dyax Corp   (United States)

^b CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; DX 2647; IMMUNOGLOBULIN G; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SCREENING; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; MICE; SIGNAL TRANSDUCTION; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953440123     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1134     Document Type: Article

References (48)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
2. Spangenberg HC, Thimme R, Blum HE. Evolving therapies in the treatment of hepatocellular carcinoma. Biologics 2008;2:453-62.
3. Breuhahn K, Schirmacher P. Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J Gastroenterol 2008;14:1690-8.
4. Chao W, D'Amore PA. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 2008;19:111-20.
5. Duguay SJ, Jin Y, Stein J, Duguay AN, Gardner P, Steiner DF. Posttranslational processing of the insulin-like growth factor-2 precursor. Analysis of O-glycosylation and endoproteolysis. J Biol Chem 1998; 273:18443-51. (Pubitemid 28334772)
6. Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med 1988;319:1434-40.
7. Elmlinger MW, Rauschnabel U, Koscielniak E, Weber K, Ranke MB. Secretion of noncomplexed 'Big' (10-18 kD) forms of insulin-like growth factor-II by 12 soft tissue sarcoma cell lines. Horm Res 1999;52:178-85. (Pubitemid 30145266)
8. Ng IO, Lee JM, Srivastava G, Ng M. Expression of insulin-like growth factor II mRNA in hepatocellular carcinoma. J Gastroenterol Hepatol 1998;13:152-7. (Pubitemid 28137914)
9. Uchida K, Kondo M, Takeda S, et al. Altered transcriptional regulation of the insulin-like growth factor 2 gene in human hepatocellular carcinoma. Mol Carcinog 1997;18:193-8. (Pubitemid 27208217)
10. Cariani E, Lasserre C, Seurin D, et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 1988;48:6844-9. (Pubitemid 19012216)
11. Park BC, Huh MH, Seo JH. Differential expression of transforming growth factor α and insulin-like growth factor II in chronic active hepatitis B, cirrhosis and hepatocellular carcinoma. J Hepatol 1995;22: 286-94.
12. Dong ZZ, Yao DF, Yao DB, et al. Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol 2005;11:4655-60.
13. Rogler CE, Yang D, Rossetti L, et al. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 1994;269:13779-84. (Pubitemid 24191120)
14. Cariani E, Dubois N, Lasserre C, Briand P, Brechot C. Insulin-like growth factor II (IGF-II) mRNA expression during hepatocarcinogenesis in transgenic mice. J Hepatol 1991;13:220-6.
15. Schirmacher P, Held WA, Yang D, Chisari FV, Rustum Y, Rogler CE. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res 1992;52:2549-56.
16. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003;107:873-7.
17. Sell C, Dumenil G, Deveaud C, et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994;14:3604-12. (Pubitemid 24160768)
18. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A 1993;90:11217-21. (Pubitemid 23354400)
19. Rodon J, DeSantos V, Ferry RJ, Jr., Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008;7:2575-88.
20. Renehan AG, Jones J, O'Dwyer ST, Shalet SM. Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: comparisons using the Bland-Altman method. Growth Horm IGF Res 2003;13:341-6. (Pubitemid 37493325)
21. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
22. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30:586-623.
23. Goya M, Miyamoto S, Nagai K, et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 2004;64: 6252-8. (Pubitemid 39129428)
24. Miyamoto S, Nakamura M, Shitara K, et al. Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers. Clin Cancer Res 2005;11:3494-502. (Pubitemid 40627904)
25. Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC, Dimitrov DS. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006;5:114-20.
26. Kimura T, Kuwata T, Ashimine S, et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res 2010;16:121-29.
27. Denley A, Bonython ER, Booker GW, et al. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol Endocrinol 2004;18:2502-12. (Pubitemid 39335984)
28. Soon L, Flechner L, Gutkind JS, et al. Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression. Mol Cell Biol 1999;19:3816-28. (Pubitemid 29193841)
29. Newman J, Cohen EH, Cosgrove L, et al. Crystallization and preliminary X-ray analysis of the complexes between a Fab and two forms of human insulin-like growth factor II. Acta Crystallogr Sect F Struct Biol Cryst Commun 2009;65:945-8.
30. Newman J. Novel buffer systems for macromolecular crystallization. Acta Crystallogr D Biol Crystallogr 2004;60:610-2.
31. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994;50:760-3.
32. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004;60:2126-32.
33. Hoet RM, Cohen EH, Kent RB, et al. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining- region diversity. Nat Biotechnol 2005;23:344-8.
34. Brown J, Delaine C, Zaccheo OJ, et al. Structure and functional analysis of the IGF-II/IGF2R interaction. EMBO J 2008;27:265-76.
35. Divisova J, Kuiatse I, Lazard Z, et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 2006;98:315-27. (Pubitemid 44195602)
36. Yin D, Vreeland F, Schaaf LJ, et al. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 2007;13:1000-9. (Pubitemid 46340379)
37. Lund P, Schubert D, Niketeghad F, Schirmacher P. Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II. Cancer Lett 2004;206:85-96. (Pubitemid 38281258)
38. Nussbaum T, Samarin J, Ehemann V, et al. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 2008;48:146-56. (Pubitemid 351975539)
39. Zaccheo OJ, Prince SN, Miller DM, et al. Kinetics of insulin-like growth factor II (IGF-II) interaction with domain 11 of the human IGF-II/mannose 6-phosphate receptor: function of CD and AB loop solvent-exposed residues. J Mol Biol 2006;359:403-21.
40. Yao X, Hu JF, Daniels M, et al. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest 2003;111:265-73.
41. Yao X, Hu JF, Daniels M, et al. A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin Cancer Res 2003;9:2719-26.
42. Kim KW, Bae SK, Lee OH, Bae MH, Lee MJ, Park BC. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 1998;58:348-51.
43. Lee OH, Bae SK, Bae MH, et al. Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models. Br J Cancer 2000;82:385-91.
44. Ritter MR, Dorrell MI, Edmonds J, Friedlander SF, Friedlander M. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci U S A 2002;99:7455-60.
45. Volpert O, Jackson D, Bouck N, Linzer DI. The insulin-like growth factor II/mannose 6-phosphate receptor is required for proliferin-induced angiogenesis. Endocrinology 1996;137:3871-6.
46. Maeng YS, Choi HJ, Kwon JY, et al. Endothelial progenitor cell homing: prominent role of the IGF2-IGF2R-PLCβ2 axis. Blood 2009;113: 233-43.
47. Bond JJ, Meka S, Baxter RC. Binding characteristics of pro-insulin-like growth factor-II from cancer patients: binary and ternary complex formation with IGF binding proteins-1 to -6. J Endocrinol 2000;165: 253-60.
48. Krissinel E, Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr 2004;60:2256-68.